Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
l�ll
Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia Buchanan RW; Freedman R; Javitt DC; Abi-Dargham A; Lieberman JASchizophr Bull 2007[Sep]; 33 (5): 1120-30Wayne Fenton was a major driving force behind the establishment of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) and Treatment Units for Research on Neurocognition and Schizophrenia (TURNS) project mechanisms. These projects were designed to facilitate the development of new drugs for the treatment of cognitive impairments in people with schizophrenia. The MATRICS project identified 3 drug mechanisms of particular interest: cholinergic, dopaminergic, and glutamatergic. The TURNS project is designed to select potential cognitive-enhancing agents and evaluate their potential efficacy in the context of proof of concept or clinical efficacy trials. This article reviews the rationale for these 3 approaches and provides an update on the development of therapeutic agents, which act through one of these 3 mechanisms.|*Drug Design[MESH]|*Schizophrenic Psychology[MESH]|Antipsychotic Agents/pharmacology/*therapeutic use[MESH]|Cognition Disorders/*drug therapy/physiopathology/psychology[MESH]|Humans[MESH]|Program Development/methods[MESH]|Receptors, AMPA/drug effects/physiology[MESH]|Receptors, Dopamine/drug effects/physiology[MESH]|Receptors, Glutamate/drug effects/physiology[MESH]|Receptors, Muscarinic/drug effects/physiology[MESH]|Receptors, Nicotinic/drug effects/physiology[MESH]|Schizophrenia/*drug therapy/physiopathology[MESH] |